Cover Image

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma

Saved in:

Bibliographic Details
Main Authors:	George D. Glinos, MD (Author), William Steele Fisher, BS (Author), Claudia S. Morr, MD (Author), Lucia Seminario-Vidal, MD, PhD (Author)
Format:	Book
Published:	Elsevier, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
by: Reddy V, et al.
Published: (2020)

Nivolumab-induced lichen planus responsive to dupilumab treatment in a patient with stage III C melanoma
by: Sarah Kamsiah Zemlok, BA, et al.
Published: (2023)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
by: Cara Barber, MD, MPH, et al.
Published: (2022)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
by: Kanako Tsunoda, MD, PhD, et al.
Published: (2024)

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
by: Margaux Dubus, MD, et al.
Published: (2023)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022)

Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
by: Sophia Wix, MPhil, et al.
Published: (2023)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
by: Angelo Ruggiero, et al.
Published: (2022)

Acquired perforating dermatosis associated with risankizumab
by: Munira Alhadlg, MD, et al.
Published: (2024)

Risankizumab-associated lichen planus pemphigoides
by: Jessica Sparks, et al.
Published: (2023)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022)

A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin
by: Alexa DeMaio, MD, et al.
Published: (2023)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018)

Eosinophilic fasciitis in association with nivolumab: The importance of eosinophilia
by: Gabriela Pabón-Cartagena, MD, et al.
Published: (2020)

Psoriasiform eruption on the face and extremities associated with nivolumab therapy
by: Amit Om, MD, et al.
Published: (2018)

Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
by: Edouard Chasseuil, et al.
Published: (2018)

Clinical utility of nivolumab in the treatment of advanced melanoma
by: Asmar R, et al.
Published: (2016)

Inverse lichenoid drug eruption associated with nivolumab
by: Lauren M. Guggina, MD, et al.
Published: (2017)

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma
by: Mathew R. Birnbaum, BS, et al.
Published: (2017)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
by: Al Muqrin AM, et al.
Published: (2022)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
by: Marta Kołt-Kamińska, et al.
Published: (2023)

Nivolumab-associated cutaneous T-cell lymphoma
by: Jennifer A. Marks, MD, et al.
Published: (2021)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018)

Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE
by: Nicoletta Bernardini, et al.
Published: (2024)

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
by: Yuka Maya, MD, et al.
Published: (2020)

Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
by: Bruno Bregman, et al.
Published: (2020)

Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab
by: Seiya Kitano, et al.
Published: (2018)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
by: Nanumi Han, et al.
Published: (2018)

Nivolumab associated vasculopathy: A novel mechanism
by: Adeeb Haroon, MS, et al.
Published: (2022)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
by: Fabrizio Calapai, et al.
Published: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022)